Thyrocare Technologies (NSE:THYROCARE) ROCE % : 17.37% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Thyrocare Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Thyrocare Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was 17.37%.

Thyrocare Technologies ROCE % Historical Data

The historical data trend for Thyrocare Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thyrocare Technologies ROCE % Chart

Thyrocare Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

33.75

36.53

46.30

16.55

18.07

Thyrocare Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															13.20	18.56	22.44	16.01	17.37

Thyrocare Technologies ROCE % Calculation

Thyrocare Technologies's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	1001.8	/	( ( (6327.2 - 771)	+	(6438.8 - 904.8) )	/ 2 )
	=	1001.8	/	( (5556.2	+	5534)	/ 2 )
	=	1001.8	/	5545.1
	=	18.07 %

Thyrocare Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	961.2	/	( ( (0 - 0)	+	(6438.8 - 904.8) )	/ 1 )
	=	961.2	/	( ( 0	+	5534 )	/ 1 )
	=	961.2	/	5534
	=	17.37 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Thyrocare Technologies (NSE:THYROCARE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Thyrocare Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Thyrocare Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Thyrocare Technologies (NSE:THYROCARE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thyrocare Technologies Ltd (NSE:THYROCARE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

539871:India

Address

D-37/1, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703

Website

https://www.thyrocare.com

Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Other. The Diagnostic Testing Services segment provides a medical diagnostic investigation into thyroid disorders, metabolism disorders, diabetes, anemia, infertility, auto-immunity, and other infectious diseases. The company primarily earns majority of its revenue from Diagnostic Testing Services segment. The Imaging Services segment operates a network of imaging centers focused on early and effective cancer monitoring. The Other business segment provides miscellaneous services. The company earns the vast majority of its revenue in India.

Thyrocare Technologies (NSE:THYROCARE) Headlines

No Headlines